# BPC-157 and new blood vessels

> BPC-157 vessels · Peptide Therapy Evidence Review — Peptide Therapy Evidence Review examines BPC-157 blood-vessel findings, rat stomach ulcers, rapid animal clearance and the small human record.

The vessel-growth paper offers a concrete mechanism. The much broader language about human healing still has a very small clinical record behind it.

## BPC-157’s stomach-ulcer experiments

BPC-157 is a synthetic peptide built from fifteen amino acids, based on a partial sequence of a protein found in human gastric juice. Its name expands to Body Protection Compound 157. The [review of musculoskeletal healing research](https://pubmed.ncbi.nlm.nih.gov/40789979/) describes how far the proposed uses have spread from that gastric starting point.

The stomach work itself has a definite subject. In [Wistar rats with gastric ulcers](https://pubmed.ncbi.nlm.nih.gov/15052688/), BPC-157 reduced ulcer area and accelerated healing, including rebuilding of the stomach lining and granulation tissue. That finding concerns injured rat stomachs. General claims about human digestion travel much further.

Faced with such a broad reputation, I turn to experiments that can explain a specific effect. Blood-vessel growth supplies one of those explanations.

## VEGFR2 and recovering blood flow

The [BPC-157 vessel-growth study](https://pubmed.ncbi.nlm.nih.gov/27847966/) used human vascular endothelial cells, the vessel-rich membrane in developing chick eggs, and rats with reduced blood supply to a hind limb. It reported increased vessel density and accelerated recovery of blood flow in the rat muscle.

The researchers followed VEGFR2, a receptor that receives a vessel-growth signal. BPC-157 increased its expression and promoted its movement into the cell, alongside activation of the VEGFR2–Akt–eNOS pathway. Interfering with that movement into the cell blocked the vessel effect.

The VEGFR2 paper wins me over where it interferes with the mechanism: that makes the proposed explanation testable. It gives the proposed mechanism something to answer to. Its scope is still cells and animals: no injured people were tested for improved recovery in this experiment.

![An adult technician examines the branching vessels of a chick egg membrane](images/chick-membrane-observation.webp)

*An imagined bench scene showing a chick membrane under magnification, one of the models used in the vessel-growth research. It represents the model, not a recorded study result.*

## The small human record

Two healthy adults took part in the [intravenous BPC-157 safety pilot](https://pubmed.ncbi.nlm.nih.gov/40131143/). No adverse events were observed, and the measured cardiac, liver, kidney, thyroid and glucose markers showed no changes. The participants were being observed for safety rather than treated for an injury.

A [2025 review](https://pubmed.ncbi.nlm.nih.gov/40789979/) counted three small human pilot studies and described the absence of rigorous large-scale trials. It also raised the limited replication of a literature built substantially by one group and its collaborators.

I accept this BPC-157 pilot as a preliminary observation. A brief look at two healthy adults leaves rare harms, later harms and the treatment of a damaged tendon unresolved.

## Animal clearance measurements

A [pharmacokinetic study in rats and beagle dogs](https://pubmed.ncbi.nlm.nih.gov/36588717/) found an elimination half-life of less than 30 minutes and rapid breakdown into smaller peptide fragments. Pharmacokinetics describes where a substance goes and how it is cleared.

The short blood half-life is a finding about those animals. It does not establish a human treatment interval or tell us how long a tissue response lasts. I trust recovery measurements more than a timetable inferred from animal clearance.

## Anecdotes about movement and symptoms

People describing BPC-157 use report easier movement, less joint discomfort and fewer gut symptoms. They also report local redness or stinging, fatigue, stomach upset, headaches, dizziness and occasional palpitations. These are anecdotal accounts, not clinical evidence. Their product contents, other care and causes of improvement have not been controlled.

The vessel-growth findings raise a theoretical concern in active or suspected cancer, because tumors also depend on a blood supply. The [angiogenesis experiment](https://pubmed.ncbi.nlm.nih.gov/27847966/) supplies a mechanism for asking that question; it did not measure cancer harm in people. Human long-term growth effects and interactions with other medicines remain uncertain.

BPC-157 is unapproved for human use and prohibited in sport. Safety during pregnancy, breastfeeding and childhood has not been established. The [safety page](/safety) places those gaps beside the brief human observations.

---

An independent evidence desk for repair-peptide studies, keeping every tissue claim beside its comparator and outside the bounds of medical advice.